US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-01 04:30:43 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
You may also like
- Sudanese army says will help evacuate foreign nationals
- Bayern in unrest ahead of Arsenal clash
- Asian Winter Games Harbin 2025 releases promo video
- China's Hou breaks world record at IWF World Cup
- Trojan horse or unproven fears? Into U.S. demonization of Chinese manufacturing
- Holiday tourism contributes to China's rural revitalization
- Dortmund face striker problem ahead of Atletico clash
- China's ice and snow industry shows promise in wake of Winter Olympics
- Quake death toll surpasses 15,000 in Türkiye, Syria